Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial

BACKGROUND: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial(1) prospectively obtained serum and tumor core biopsies and randomized 255 chemorefractory non–small-cell lung cancer (NSCLC) patients into four phase II trials: erlotinib, erlotinib-bexarotene, van...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Tsao, Anne S., Liu, Suyu, Lee, J. Jack, Alden, Christine M., Blumenschein, George R., Herbst, Roy, Davis, Suzanne E., Kim, Edward, Lippman, Scott, Heymach, John, Tran, Hai, Tang, XiMing, Wistuba, Ignacio, Hong, Waun Ki
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5118909/
https://ncbi.nlm.nih.gov/pubmed/23584298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31828d08ae
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados